Santen's innovative glaucoma medication, Tafluprost-Timolol Eye Drops (Taipukang®), launches in China

Santen recently announced the official launch in China of its Tafluprost-Timolol Ophthalmic Solution, TAPCOM®. TAPCOM® is the first original research fixed-combination ophthalmic formulation in China containing a prostaglandin (PG) analog—a first-line treatment for glaucoma—and is preservative-free. It is indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who respond inadequately to monotherapy with either a beta-blocker or a prostaglandin analog and require combination therapy, as well as for patients who may benefit from preservative-free eye drops.